Bardy Diagnostics™ Announces Additional Growth Capital Funding

SEATTLE, July 16, 2018 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, including the Carnation Ambulatory Monitor (“CAM™”), the world’s first P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device, announced today it has raised additional growth capital from its existing equity investors, including SV Health Investors (“SVHI”), Health Enterprise Partners, and Ascension Ventures. The growth capital will be used to expand BardyDx’s sales force and monitoring services, advance research and development programs, and accelerate development of artificial intelligence diagnostic capabilities.